BEVILACQUA, GIULIO
 Distribuzione geografica
Continente #
EU - Europa 139
NA - Nord America 102
AS - Asia 70
OC - Oceania 1
SA - Sud America 1
Totale 313
Nazione #
US - Stati Uniti d'America 96
IT - Italia 82
SG - Singapore 50
FI - Finlandia 13
BG - Bulgaria 11
SE - Svezia 10
DE - Germania 8
ID - Indonesia 8
PH - Filippine 7
CA - Canada 6
BE - Belgio 4
GB - Regno Unito 4
IN - India 3
LT - Lituania 3
CN - Cina 2
AT - Austria 1
BR - Brasile 1
ES - Italia 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 313
Città #
Rome 41
Singapore 38
Santa Clara 25
Sofia 11
Milan 9
Helsinki 8
Jakarta 8
Chandler 7
New York 6
Fairfield 5
Lappeenranta 5
Liège 4
Marikina City 4
Munich 4
Ottawa 4
Rovato 4
Cagli 3
London 3
Olongapo City 3
Princeton 3
Ashburn 2
Kurukshetra 2
Lecce 2
Naples 2
Regensburg 2
San Diego 2
Toronto 2
Alghero 1
Alicante 1
Balasore 1
Boardman 1
Boston 1
Brescia 1
Caprarola 1
Clifton 1
Falkenstein 1
Gävle 1
Hamilton 1
Hounslow 1
Lawrence 1
Los Angeles 1
Millbury 1
Moscow 1
Nuremberg 1
Reston 1
Sacramento 1
San Mateo 1
Seattle 1
Vienna 1
Wilmington 1
Totale 232
Nome #
How to predict outcomes from a biofeedback and pelvic floor muscle electric stimulation program in patients with urinary incontinence after radical prostatectomy 48
Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy 34
Comment on: Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis 29
How the analysis of the pathogenetic variants of DDR genes will change the management of prostate cancer patients 28
Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients? 23
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: a meta-analysis and systematic review 21
Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive nonmetastatic prostate cancer. Comparative analysis in terms of CRPC-M0 progression 21
Comparison of Four Validated Nomograms (Memorial Sloan Kettering Cancer Center, Briganti 2012, 2017, and 2019) Predicting Lymph Node Invasion in Patients with High-Risk Prostate Cancer Candidates for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Clinical Experience and Review of the Literature 20
How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy 19
Comparative prospective and longitudinal analysis on the platelet-to-lymphocyte, neutrophil-to-lymphocyte, and albumin-to-globulin ratio in patients with non-metastatic and metastatic prostate cancer 17
Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review 16
Real-Life Comparative Analysis of Robotic-Assisted Versus Laparoscopic Radical Prostatectomy in a Single Centre Experience 16
DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives 15
null 14
null 14
Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers’ Performance 12
The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature 11
Regenerative medicine-based treatment of stress urinary incontinence with stem cells: a systematic review and meta-analysis 9
null 4
Protein corona on nanoparticles for tumor targeting in prostate cancer. Review of the literature and experimental trial protocol 3
Totale 374
Categoria #
all - tutte 2.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.584


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202227 0 0 0 0 0 0 2 1 8 0 4 12
2022/202373 9 2 12 1 9 5 5 13 6 0 9 2
2023/2024108 6 9 10 10 9 23 2 14 0 7 5 13
2024/2025166 2 25 10 34 54 37 4 0 0 0 0 0
Totale 374